The Top 5 Biosimilar Articles for the Week of September 28

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of September 28, 2020.

Number 5: The FDA's Office of Therapeutic Biologics and Biosimilars balances a large number of biosimilar development projects with limited resources and is making progress, says Eva Temkin, acting director of policy.

Number 4:A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.

Number 3: Much emphasis is placed on the value of congressional action to reduce prescription costs, but the Center for American Progress suggests there is an existing toolkit to accomplish this objective.

Number 2: Alexion’s follow-on ravulizumab product (Ultomiris) has received marketing authorization from Japan’s Ministry of Health Labor and Welfare for treatment of adults and children with atypical hemolytic uremic syndrome (aHUS).

Number 1: The NOR-SWITCH study showed comparable safety, efficacy, and immunogenicity for patients with inflammatory bowel disease (IBD) who switched from reference infliximab to Celltrion biosimilar (CT-P13).

To read all of these articles and more, visit centerforbiosimilars.com.